Induction Backbone Selection and Platinum Rechallenge in ES-SCLC

Dr. Shields addresses choosing between atezolizumab-based (IMpower133) and durvalumab-based (CASPIAN) induction regimens, noting both demonstrate similar OS benefits (approximately 2.5-3 months) with real-world data showing general equipoise between agents. Her selection often depends on clinical trial availability requiring specific backbones, with practical considerations regarding dosing schedules (3-week versus 4-week cycles) when transitioning to maintenance.

Dr. Sands notes he prioritizes clinical trial enrollment when available, otherwise considering either backbone reasonable. For patients significantly debilitated by induction therapy needing recovery time, second-line tarlatamab represents a viable option allowing patients to heal before pursuing additional treatment.

Dr. Leal addresses the NCCN guideline reorganization removing chemotherapy-free interval qualifiers from subsequent therapy recommendations, expressing approval of this change. Trial data consistently showed platinum-sensitive and platinum-refractory patients derived similar benefit from newer agents like tarlatamab and lurbinectedin, making the previous chemotherapy-free interval distinction less clinically meaningful given current treatment options.

She acknowledges limited scenarios where platinum rechallenge might still apply, particularly in limited-stage disease with chemotherapy-free intervals exceeding 1 year without prior immunotherapy exposure, potentially restarting platinum with immunotherapy before considering enhanced maintenance. However, for most patients, she favors progressing to newer, more effective agents and clinical trials involving antibody-drug conjugates and T-cell engager combinations rather than platinum rechallenge.